CCM
SWTX

Cinctive Capital Management’s SpringWorks Therapeutics SWTX Stock Holding History

Cinctive Capital Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-40,000
Closed -$2.26M – 637
2022
Q1 		$2.26M Buy
+40,000
New +$2.29M 0.08% 310

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Cinctive Capital Management's SWTX Position: Q3 2024 in Review

Cinctive Capital Management sold out of SpringWorks Therapeutics (SWTX) in Q3 2024, closing a stake of 130,545 shares — an estimated $4.92M sold.

Cinctive Capital Management first reported a position in SWTX in Q4 2023 and held it in 3 quarters. The position peaked at $4.92M in Q2 2024. 226 funds tracked by Wall St. Rank hold SWTX as of Q3 2024.

  • Cinctive Capital Management reported no remaining SpringWorks Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Cinctive Capital Management sold 130,545 SpringWorks Therapeutics shares in Q3 2024, an estimated $4.92M.
  • Cinctive Capital Management first reported a position in SpringWorks Therapeutics in Q4 2023 and held it in 3 quarters.
  • Cinctive Capital Management's SpringWorks Therapeutics position peaked at $4.92M in Q2 2024.
  • 226 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2024.

Based on Cinctive Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.